as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹10.84
Change
-0.04 (-0.37%)
Open
₹10.9
Prev. Close
₹10.88
Day High
₹11.0
Day Low
₹10.61
Volume Analysis
Traded
103,563
Delivered
76,506
Delivery %
73.87%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (4)
- •Low return on equity (-31.3%)
- •Promoter holding is falling
- •Below-average fundamentals quality score (30/100)
- •Low operating margin (-3520.0%)
Opportunities (0)
No signal for this stock
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹11.42 | ₹11.21 | ₹11.03 | ₹10.82 | ₹10.64 | ₹10.43 | ₹10.25 |
| Fibonacci | ₹11.21 | ₹11.06 | ₹10.97 | ₹10.82 | ₹10.67 | ₹10.58 | ₹10.43 |
| Camarilla | ₹10.95 | ₹10.91 | ₹10.88 | ₹10.82 | ₹10.8 | ₹10.77 | ₹10.73 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-46.81%
1 Week
-0.82%
1 Month
-13.07%
3 Months
-6.31%
6 Months
+11.07%
1 Year
-24.83%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
-0.0%
Net margin -12250.0% × asset turnover 0.0x × equity multiplier 1.07x
Company Overview
Sector
Healthcare
Market Cap
₹211 Cr
ROE
-31.3%
Book Value
₹30.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 26 Sep 2026. Not investment advice.
TopFund Analysis
Nectar Lifesciences Ltd. scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 30/100. The strongest factor is Financial Strength (100/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (-31.3%); promoter holding is falling. FII holding has been falling.
TopFund Score — Fundamentals Quality
30/100 — WeakData confidence: 74/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has reduced debt.
- +Company is almost debt free.
- +Stock is trading at 0.36 times its book value
- −Company has low interest coverage ratio.
- −Company has a low return on equity of -12.3% over last 3 years.
- −Contingent liabilities of Rs.269 Cr.
- −Promoter holding has decreased over last 3 years: -3.96%
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Revised 31st AGM proceedings on Sept 18, 2026; cut-off date corrected, directors reappointed, financials adopted.
Nectar Lifesciences' 31st AGM is on September 18, 2026; annual report and e-voting details shared.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 394 | 398 | 452 | 441 | 359 | 6 | 0 | 0 | 5 | 1 | 0 | 1 | 0 |
| Expenses + | 359 | 371 | 410 | 393 | 319 | 6 | 0 | 0 | 6 | 0 | 2 | 59 | 28 |
| Operating Profit | 36 | 27 | 42 | 48 | 40 | -1 | 0 | 0 | -1 | 1 | -2 | -57 | -27 |
| OPM % | 9.0% | 7.0% | 9.0% | 11.0% | 11.0% | -10.0% | -500.0% | -500.0% | -16.0% | 77.0% | — | -4,437.0% | -6,198.0% |
| Other Income + | 0 | 11 | 0 | 1 | 1 | 7 | 8 | -130 | -62 | -176 | 35 | -24 | 3 |
| Interest | 18 | 21 | 25 | 24 | 20 | 0 | 0 | 0 | 0 | 0 | 30 | 6 | 0 |
| Depreciation | 15 | 15 | 15 | 15 | 15 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Profit before tax | 3 | 2 | 2 | 11 | 5 | 5 | 8 | -130 | -64 | -176 | 3 | -88 | -24 |
| Tax % | 41.0% | 38.0% | 36.0% | 95.0% | 40.0% | -2.0% | 2.0% | 0.0% | -1.0% | 0.0% | -339.0% | -22.0% | -37.0% |
| Net Profit + | 2 | 1 | 2 | 1 | 3 | 6 | 8 | -130 | -63 | -176 | 14 | -68 | -15 |
| EPS in Rs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -6 | -3 | -8 | 1 | -4 | -1 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,638 | 1,674 | 1,635 | 1,874 | 2,779 | 2,363 | 1,541 | 1,665 | 1,520 | 1,682 | 1,664 | 0 | 2 |
| Expenses + | 1,371 | 1,436 | 1,411 | 1,638 | 2,514 | 2,143 | 1,432 | 1,507 | 1,467 | 1,530 | 1,694 | 8 | 88 |
| Operating Profit | 267 | 239 | 224 | 236 | 264 | 220 | 109 | 159 | 53 | 152 | -30 | -8 | -86 |
| OPM % | 16.0% | 14.0% | 14.0% | 13.0% | 10.0% | 9.0% | 7.0% | 10.0% | 3.5% | 9.0% | -1.8% | -2,920.0% | -3,520.0% |
| Other Income + | 20 | 6 | 23 | 6 | 6 | 4 | -22 | 11 | 43 | 15 | 5 | -279 | -162 |
| Interest | 126 | 123 | 117 | 115 | 148 | 126 | 112 | 79 | 79 | 87 | 75 | 36 | 36 |
| Depreciation | 77 | 57 | 62 | 64 | 63 | 61 | 60 | 57 | 59 | 61 | 62 | 0 | 0 |
| Profit before tax | 85 | 64 | 67 | 63 | 59 | 37 | -85 | 34 | -42 | 18 | -162 | -323 | -285 |
| Tax % | 22.0% | 15.0% | 18.0% | 17.0% | 19.0% | 15.0% | -14.0% | 26.0% | -43.0% | 73.0% | -30.0% | -9.0% | — |
| Net Profit + | 66 | 54 | 55 | 52 | 48 | 32 | -73 | 25 | -24 | 5 | -114 | -293 | -245 |
| EPS in Rs | 3 | 2 | 2 | 2 | 2 | 1 | -3 | 1 | -1 | 0 | -5 | -15 | -12 |
| Dividend Payout % | 3.0% | 4.0% | 2.0% | 2.0% | 2.0% | 4.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 936 | 932 | 984 | 1,036 | 1,083 | 1,114 | 1,040 | 1,065 | 1,042 | 1,047 | 934 | 563 |
| Borrowings + | 925 | 962 | 878 | 955 | 903 | 779 | 903 | 860 | 754 | 636 | 582 | 0 |
| Other Liabilities + | 628 | 640 | 696 | 710 | 696 | 718 | 423 | 443 | 371 | 486 | 509 | 39 |
| Total Liabilities | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,388 | 2,391 | 2,189 | 2,191 | 2,047 | 622 |
| Fixed Assets + | 934 | 906 | 881 | 852 | 825 | 785 | 772 | 723 | 662 | 643 | 633 | 105 |
| CWIP | 91 | 99 | 102 | 100 | 100 | 115 | 99 | 85 | 78 | 66 | 57 | 0 |
| Investments | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 13 |
| Other Assets + | 1,485 | 1,551 | 1,597 | 1,771 | 1,780 | 1,733 | 1,517 | 1,582 | 1,449 | 1,482 | 1,357 | 504 |
| Total Assets | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,388 | 2,391 | 2,189 | 2,191 | 2,047 | 622 |
| Equity Capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 19 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 144 | 169 | 199 | 65 | 239 | 285 | 21 | 95 | 134 | 225 | 169 | -349 |
| Cash from Investing Activity + | -60 | -77 | -18 | -29 | -26 | -33 | -29 | 17 | 52 | -17 | -42 | 1,208 |
| Cash from Financing Activity + | -61 | -89 | -204 | -40 | -201 | -252 | 11 | -119 | -186 | -205 | -128 | -767 |
| Net Cash Flow | 23 | 3 | -23 | -4 | 12 | 0 | 4 | -8 | 0 | 2 | -1 | 93 |
| CFO/OP | 56 | 74 | 92 | 33 | 96 | 134 | 23 | 60 | 252 | 148 | -574 | 4,132 |
| Free Cash Flow | 64 | 87 | 174 | 32 | 204 | 249 | -10 | 110 | 183 | 195 | 126 | -341 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 28.17% | 28.05% | 27.2% | 27.57% | 40.94% | 54.72% | 53.64% | 54.45% | 54.37% | 48.73% | 43.52% | 43.9% |
| Promoters | 55.8% | 55.8% | 55.8% | 55.8% | 55.8% | 44.53% | 44.53% | 44.53% | 44.91% | 44.91% | 51.84% | 51.84% |
| Government | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 5.84% | 4.03% | 3.75% |
| FII | 16.02% | 16.12% | 16.98% | 16.6% | 3.24% | 0.73% | 1.65% | 0.82% | 0.62% | 0.52% | 0.6% | 0.5% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.15% | 0.19% | 0.08% | 0.0% | 0.01% | 0.01% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Nectar Lifesciences Ltd. (this stock) | 211 | — | 0.36 | -31.3% |
| Take Limited | 229 | 38.9 | 7.38 | 16.5% |
| Brooks Lab Limited | 180 | 13.7 | 1.47 | 22.0% |
| Natural Capsules Limited | 176 | — | 1.01 | -9.45% |
| Bal Pharma Ltd. | 175 | 24.4 | 2.13 | 7.87% |
| Bilcare Ltd. | 257 | 12.9 | 1.3 | 1.39% |
| Parnax Lab Ltd. | 149 | 14.8 | 1.56 | 14.4% |
Which Mutual Funds Hold Nectar Lifesciences Ltd.?
Frequently Asked Questions about Nectar Lifesciences Ltd.
Nectar Lifesciences Ltd. (NECLIFE) closed at ₹10.84 on NSE on 25 September 2026, down 0.04 (0.37%) from the previous close.
Nectar Lifesciences Ltd. trades on the NSE (National Stock Exchange of India) under the symbol NECLIFE.
Nectar Lifesciences Ltd. has a dividend yield of 0.0%.
Nectar Lifesciences Ltd.'s 52-week high is ₹22.5 and its 52-week low is ₹9.2.
Nectar Lifesciences Ltd. has a market capitalisation of ₹211 crore.
Nectar Lifesciences Ltd. has a TopFund Quality Score of 30/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Nectar Lifesciences Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.